文献速递神经免疫

早期静脉注射免疫球蛋白与抗IgLON5病患者的预后

Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 Disease.
PubMed 文献 · JAMA Neurol · 2025-01-01

该回顾性多中心队列研究纳入107例抗IgLON5病患者,中位随访66个月,发现早期免疫治疗与较低长期残疾和生存相关;仅发病第一年内启动静脉注射免疫球蛋白与较低mRS评分和较低死亡比例相关。

要点

  • 早期免疫治疗是唯一可修饰的独立因素,与较低长期残疾和生存相关。
  • 仅发病第一年内静脉注射免疫球蛋白与较低mRS评分和较低死亡比例相关。
  • 研究为回顾性设计,需更大型前瞻性研究验证。

核心结论

  • 发病第一年内启动静脉注射免疫球蛋白与抗IgLON5病较好的长期结局和生存改善相关。

研究设计与样本

  • 回顾性多中心队列研究,纳入107例抗IgLON5病患者,中位随访66个月。

主要发现

  • 25例(23.4%)在发病第一年内接受免疫治疗,57例(53.3%) later接受。

临床怎么用

  • 对于抗IgLON5病患者,可考虑在发病第一年内启动静脉注射免疫球蛋白治疗。

局限性

  • 回顾性设计,需更大型前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anti-IgLON5 disease is an autoimmune encephalopathy that often leads to severe disability or death. The efficacy of immunotherapy remains unknown. OBJECTIVE: To investigate whether early immunotherapy is associated with disability and death in anti-IgLON5 disease. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter cohort study of patients with anti-IgLON5 disease was conducted from 2014 to 2024, with a median (IQR) follow-up of 66 (33-97) months after disease onset. Data from the German Network for Research on Autoimmune Encephalitis Registry, University Hospital Clinic of Barcelona (Spain), and Erasmus University Medical Center (the Netherlands) were analyzed. Eligibility criteria were clinical features consistent with anti-IgLON5 disease and the presence of IgLON5 antibodies in serum or cerebrospinal fluid. Data were collected by treating physicians using a structured questionnaire. Of 121 patients systematically selected from participating centers and registries, 14 patients were excluded due to insufficient clinical information or withdrawal of consent. INTERVENTION: Initiation of immunotherapy based on the treating physician's decision. MAIN OUTCOMES AND MEASURES: Clinical disability was assessed using the modified Rankin Scale (mRS) at the most recent follow-up visit and the proportion of patients who died. RESULTS: Among 107 patients with anti-IgLON5 disease (46 female [43.0%] and 61 male [57.0%]; median [IQR] age at the time of disease onset, 64 [57-70] years), 25 patients (23.4%) received immunotherapy during the first year of disease onset and 57 patients (53.3%) received it later. Among early treated patients, 9 individuals (36.0%) received intravenous immunoglobulins and 13 individuals (52.0%) received rituximab. A total of 44 patients (41.1%) died, and at least two-thirds of these deaths were related to anti-IgLON5 disease (28 patients [63.6%]). Early immunotherapy was the only modifiable independent factor associated with a lower long-term disability (odds ratio, 0.32; 95% CI, 0.13-0.83; P = .02) and survival (odds ratio, 2.70; 95% CI, 0.99-7.69; P = .047). Only intravenous immunoglobulin started within the first year of disease onset was associated with a lower median (IQR) mRS score at the most recent follow-up (2 [1-2.5] vs 3 [2-6]; P = .005; r = 0.55) and a lower proportion of deaths (0 of 9 patients vs 6 of 16 patients [37.5%]; P = .04) compared with other early immunotherapies despite a similar baseline mRS score. CONCLUSIONS AND RELEVANCE: In this study, early initiation of intravenous immunoglobulins (within the first year of onset) was associated with favorable long-term outcomes and improved survival in anti-IgLON5 disease. Larger prospective studies are needed to validate this finding.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Grüter T, Gaig C, Crijnen YS, et al. Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 Disease. JAMA Neurol. 2025. PMID: 40758377. doi:10.1001/jamaneurol.2025.2574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。